ArticleSultan Qaboos University medical journal2025
Successful Treatment of Recalcitrant Eosinophilic Pustular Folliculitis with Dupilumab.
Article in Sultan Qaboos University medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Eosinophilic pustular folliculitis: The successful identification and treatment of clinically and histologically variable presentations.JAAD case reports · 2026Article
- Upadacitinib Induces Rapid Remission in Refractory Eosinophilic Pustular Folliculitis with Facial Involvement: A Case Report.Acta dermato-venereologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic pustular folliculitis (EPF) is a chronic inflammatory condition characterised by the appearance of excoriated papules involving the face, neck, trunk, and root of limbs. It is a rare disease, and most treatments rely on reports of isolated cases or small case series. Numerous treatments have been employed throughout history, with variable effectiveness, including indomethacin, corticosteroids, calcineurin inhibitors, dapsone, cyclosporine, tetracyclines, isotretinoin or narrowband ultraviolet B therapy. We report the successful treatment of a 77-year-old female patient who presented to a tertiary care hospital in Valencia, Spain, in 2024 with refractory EPF, which significantly affected her quality of life due to uncontrollable pruritus, with dupilumab. With the advent of new biologic drugs and small molecule therapies, it is hoped that diseases traditionally lacking effective treatments will have new valid and safe treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.